EXPLAINED: 4 | Rare Historical Photos

His dad worked on the factory floor at Johnson & Johnson. Now he’s the CFO

Joe Wolk, with J&J for over 25 years, talks about his path and the company's focus on innovation.

Fortune · Dec 6, 2023

South Africa, Colombia and others are fighting drugmakers over access to TB and HIV drugs

In a series of moves experts say signal a shift in how developing countries deal with pharmaceuticals, South Africa, Colombia and others have recently adopted a more combative approach towards drugmakers, pushing back on policies that deny treatment to millions of people with tuberculosis and HIV

The Independent UK · Nov 24, 2023

2 Dividend Kings Warren Buffett Just Dumped

The legendary value investor slashed two consistent dividend-paying stocks from Berkshire Hathaway's portfolio in the latest quarter, according to regulatory filings.

Barchart · Nov 20, 2023

Johnson & Johnson is getting rid of its script logo after more than 130 years

Johnson & Johnson is signing off on a new logo, more than 130 years after creating the old one

The Independent UK · Sep 14, 2023

South Africa ‘held to ransom’ by big pharma, overcharged for COVID vaccines

J&J, Pfizer charged South Africa between 15 and 33 percent more for COVID vaccine doses, contracts reveal.

Al Jazeera · Sep 6, 2023

Cost of tuberculosis treatment halved in deal to permit generic versions

Johnson & Johnson’s year-long deal on life-saving drug bedaquiline is seen as critical move in campaign against disease

The Guardian - UK · Aug 31, 2023

Kenvue Joins S&P 500 on Friday: Time to Buy?

S&P Dow Jones Indices announced on Monday that Kenvue would join the S&P 500 on Friday. Tuesday’s volume and rising share price suggest that investors feel now is the time to buy its stock.

Barchart · Aug 22, 2023

Newest Fortune 500 member says large companies lose focus: 'You are little more remote from where the action is'

Kenvue, spun off from Johnson & Johnson in May, generated $15 billion in sales last year, enough to put it at rank 275 on 2022's Fortune 500 list.

Fortune · Jul 24, 2023

Explained | Will generic supply of bedaquiline be accessible?

J&J's patent on bedaquiline expired, allowing generic manufacturers to supply the drug. J&J has filed secondary patents. Prices are expected to reduce 3-6x, but some countries are excluded from the deal, raising concerns.

The Hindu · Jul 24, 2023

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India

MSF reiterated its call for Johnson & Johnson to publicly announce that it will not enforce any ‘secondary’ patents for bedaquiline in any country with a high burden of TB, as J&J’s 20-year primary patent on bedaquiline expired on July 18.

The Hindu · Jul 19, 2023